Shares of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) have earned an average recommendation of “Hold” from the eleven analysts that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and three have assigned a buy rating to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $16.92.
Several research analysts have weighed in on AMAG shares. Cowen reiterated a “hold” rating and issued a $13.00 price objective on shares of AMAG Pharmaceuticals in a research note on Monday, June 24th. Barclays reiterated a “hold” rating on shares of Bank of Montreal in a research note on Tuesday, June 11th. ValuEngine lowered shares of Zynerba Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, May 28th. BidaskClub upgraded shares of Zai Lab from a “buy” rating to a “strong-buy” rating in a research note on Friday, June 28th. Finally, Zacks Investment Research upgraded shares of Hanmi Financial from a “sell” rating to a “hold” rating in a research note on Thursday, June 20th.
AMAG Pharmaceuticals stock traded up $0.04 during trading hours on Friday, hitting $9.27. The company had a trading volume of 581,492 shares, compared to its average volume of 1,280,605. The firm has a market capitalization of $313.05 million, a price-to-earnings ratio of -2.39 and a beta of 0.47. The company has a quick ratio of 2.13, a current ratio of 2.30 and a debt-to-equity ratio of 0.44. The company’s fifty day moving average is $9.56. AMAG Pharmaceuticals has a fifty-two week low of $7.81 and a fifty-two week high of $26.10.
AMAG Pharmaceuticals (NASDAQ:AMAG) last released its quarterly earnings data on Tuesday, May 7th. The specialty pharmaceutical company reported ($3.32) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.55) by ($2.77). The company had revenue of $75.80 million during the quarter, compared to analyst estimates of $90.13 million. AMAG Pharmaceuticals had a negative net margin of 30.90% and a negative return on equity of 26.33%. The firm’s quarterly revenue was down 35.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($1.59) EPS. As a group, analysts expect that AMAG Pharmaceuticals will post -2.15 EPS for the current year.
In other news, CEO William K. Heiden acquired 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 9th. The stock was acquired at an average cost of $10.70 per share, with a total value of $107,000.00. Following the acquisition, the chief executive officer now owns 490,056 shares in the company, valued at $5,243,599.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Elizabeth Scott Bolgiano acquired 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 9th. The shares were purchased at an average cost of $10.93 per share, with a total value of $54,650.00. Following the completion of the acquisition, the insider now owns 74,847 shares in the company, valued at approximately $818,077.71. The disclosure for this purchase can be found here. In the last 90 days, insiders have bought 328,016 shares of company stock worth $2,904,577. 4.90% of the stock is currently owned by company insiders.
Several hedge funds and other institutional investors have recently bought and sold shares of the stock. California Public Employees Retirement System boosted its holdings in shares of AMAG Pharmaceuticals by 0.8% during the 4th quarter. California Public Employees Retirement System now owns 86,987 shares of the specialty pharmaceutical company’s stock worth $1,321,000 after buying an additional 690 shares during the period. Texas Permanent School Fund boosted its holdings in shares of AMAG Pharmaceuticals by 4.2% during the 4th quarter. Texas Permanent School Fund now owns 22,600 shares of the specialty pharmaceutical company’s stock worth $343,000 after buying an additional 909 shares during the period. NumerixS Investment Technologies Inc boosted its holdings in shares of AMAG Pharmaceuticals by 17.8% during the 1st quarter. NumerixS Investment Technologies Inc now owns 7,166 shares of the specialty pharmaceutical company’s stock worth $90,000 after buying an additional 1,083 shares during the period. Rhumbline Advisers boosted its holdings in shares of AMAG Pharmaceuticals by 1.1% during the 1st quarter. Rhumbline Advisers now owns 103,866 shares of the specialty pharmaceutical company’s stock worth $1,338,000 after buying an additional 1,125 shares during the period. Finally, Principal Financial Group Inc. boosted its holdings in shares of AMAG Pharmaceuticals by 0.6% during the 4th quarter. Principal Financial Group Inc. now owns 285,332 shares of the specialty pharmaceutical company’s stock worth $4,334,000 after buying an additional 1,613 shares during the period.
AMAG Pharmaceuticals Company Profile
AMAG Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and commercializes therapeutics for maternal and women's health, anemia management, and cancer supportive care in the United States. It markets Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds.
Further Reading: Are sell-side analysts objective?
Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.